Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
Status: open16-186 - A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer
Treatment for Cervical Cancer
Description
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation. IRB Number 16-186
Sponsors
This trial is sponsored by Merck.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
![Jennifer Scalaci]()
View ProfileJennifer M. Scalici, M.D.Gynecologic OncologistAssociate Professor of Interdisciplinary Clinical Oncology
Sub Investigators
![Rocconi Rodney]()
View ProfileRodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Chief of Gynecologic Oncology Service; Associate Director for Clinical Research, Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology
